Detalles de la búsqueda
1.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
2.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
3.
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Cancer Immunol Immunother
; 72(11): 3543-3558, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37550428
4.
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
BMC Cancer
; 23(1): 1046, 2023 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37904096
5.
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.
Jpn J Clin Oncol
; 52(12): 1416-1422, 2022 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047806
6.
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
Br J Cancer
; 122(10): 1507-1517, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203221
7.
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer.
Cancer Sci
; 109(11): 3461-3470, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30142697
8.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Gastric Cancer
; 21(5): 792-801, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29353332
9.
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Anticancer Drugs
; 28(10): 1166-1173, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28906258
10.
Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients.
Anticancer Drugs
; 27(9): 891-8, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27272413
11.
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.
Front Oncol
; 14: 1379013, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38846982
12.
A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
Thyroid
; 34(4): 467-476, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38343359
13.
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Anticancer Res
; 43(10): 4701-4708, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772560
14.
Human STEAP3 maintains tumor growth under hypoferric condition.
Exp Cell Res
; 317(18): 2582-91, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21871451
15.
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Cancer Manag Res
; 14: 1641-1651, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35535266
16.
Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Clin Genitourin Cancer
; 20(5): 499.e1-499.e8, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35624001
17.
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Onco Targets Ther
; 15: 1321-1330, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36388155
18.
Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
In Vivo
; 35(5): 2869-2874, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34410980
19.
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Cancer Manag Res
; 13: 8049-8056, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34729023
20.
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Sci Rep
; 11(1): 2741, 2021 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33531609